TY - JOUR
T1 - Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis
T2 - A double-blind, placebo-controlled trial on symptomatic patients
AU - Battezzati, P. M.
AU - Zuin, M.
AU - Crosignani, A.
AU - Allocca, M.
AU - Invernizzi, P.
AU - Selmi, C.
AU - Villa, E.
AU - Podda, M.
PY - 2001
Y1 - 2001
N2 - Background: Combined medical treatment may provide further benefit to primary biliary cirrhosis (PBC) patients administered ursodeoxycholic acid (UDCA). Aim: To evaluate the long-term effects of colchicine and UDCA in symptomatic PBC patients. Patients/methods: We extended up to 10 years the double-blind treatment of 44 symptomatic PBC patients originally included in a 3-year multicentre study comparing UDCA and colchicine (U + C) versus UDCA and placebo (U + P). Outcome measures were death or liver transplantation; incidence of clinically relevant events; clinical and quantitative variables retaining prognostic information. Results: Mean follow-up was 7 ± 3 years. One patient was lost, three withdrew because of jaundice (U + P); two patients stopped colchicine but remained on UDCA. Eleven patients (two for liver-unrelated reasons. U + P) and six patients (U + C) died, three and two patients, respectively, were transplanted (incidence rate difference, five cases per 100 patient-years; 95% CI, -1 to 11). Hepatocellular carcinoma developed in one (U + P) and four (U + C) patients (difference, -2; CI, -5 to 1). portal hypertension complications in nine patients from each group (difference. 1; CI, -5 to 6). Trends of serum bilirubin, Mayo score, antipyrine clearance were similar among treatment groups. Conclusions: In cirrhotic PBC patients, colchicine does not offer additional benefits to UDCA. In this population, UDCA does not obviate disease progression.
AB - Background: Combined medical treatment may provide further benefit to primary biliary cirrhosis (PBC) patients administered ursodeoxycholic acid (UDCA). Aim: To evaluate the long-term effects of colchicine and UDCA in symptomatic PBC patients. Patients/methods: We extended up to 10 years the double-blind treatment of 44 symptomatic PBC patients originally included in a 3-year multicentre study comparing UDCA and colchicine (U + C) versus UDCA and placebo (U + P). Outcome measures were death or liver transplantation; incidence of clinically relevant events; clinical and quantitative variables retaining prognostic information. Results: Mean follow-up was 7 ± 3 years. One patient was lost, three withdrew because of jaundice (U + P); two patients stopped colchicine but remained on UDCA. Eleven patients (two for liver-unrelated reasons. U + P) and six patients (U + C) died, three and two patients, respectively, were transplanted (incidence rate difference, five cases per 100 patient-years; 95% CI, -1 to 11). Hepatocellular carcinoma developed in one (U + P) and four (U + C) patients (difference, -2; CI, -5 to 1). portal hypertension complications in nine patients from each group (difference. 1; CI, -5 to 6). Trends of serum bilirubin, Mayo score, antipyrine clearance were similar among treatment groups. Conclusions: In cirrhotic PBC patients, colchicine does not offer additional benefits to UDCA. In this population, UDCA does not obviate disease progression.
UR - http://www.scopus.com/inward/record.url?scp=0034847024&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034847024&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2036.2001.01018.x
DO - 10.1046/j.1365-2036.2001.01018.x
M3 - Article
C2 - 11552915
AN - SCOPUS:0034847024
VL - 15
SP - 1427
EP - 1434
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
SN - 0269-2813
IS - 9
ER -